FDA-Drug2026-03-11Class IIIPROCESSING DEFECT

Cipla Nilotinib 200 mg capsules recalled for failed quality specifications

OTHERNationwide distributionDrugs

What this means

Cipla USA is recalling Nilotinib 200 mg capsules (Lot 5GJ0223, expiring 04/30/2027) because the capsules failed quality tests during stability testing. The capsules may not meet appearance and description standards, which means their safety and effectiveness cannot be guaranteed.

  • Stop taking this medication if you have Lot 5GJ0223.
  • Contact your doctor or pharmacist right away for a replacement or alternative treatment.
  • Do not flush or throw away the medication—ask your pharmacist how to safely dispose of it.
Get recalls like this in a free plain-English brief every Sunday.Get alerts ↓
The agency's original wording
Hazard

Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

Intended for
Adults
Illnesses reported
None reported
Sold states
U.S.A. Nationwide
Affected count
164 cartons
Manufactured in
10 Independence Blvd, N/A, Warren, NJ, United States
Products
Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each), NDC 69097-032-74; Inner carton: 28 capsules (4 blisters of 7 capsules), NDC 69097-032-56; Foil blister: NDC 69097-032-17

Official notice

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0382-2026

More Cipla recalls

Want us to check the next one for you?

We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.

Free · One email a week · Unsubscribe anytime
By signing up you agree to our Terms and Privacy Policy.